Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.

"Transparency declarations: T.P.L.: AbbVie (Consultant), BioFire Diagnostics (Grant/Research Support), Cidara (Advisor/Consultant), Entasis (Grant/Research Support), Ferring (Advisor/Consultant/Speaker), Genentech (Consultant), ICPD (Consultant), Johnson & Johnson (Consultant), Melinta (Advisor/Consultant), Merck (Advisor/Consultant, Grant/Research Support), Paratek (Advisor/Consultant), Roche (Consultant), Shionogi (Advisor/Consultant/Speaker), Spero (Advisor/Consultant), Wockhardt (Grant/Research Support) and Venatorx (Advisor/Consultant). B.H.N.: Merck (Consultant), EviMed (Consultant). E.Y., E.N.O. and A.H.W. are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.: Author contributionsT.P.L. and B.H.N. led the development of the research question, study design, implementation of the study protocol, analysis and interpretation of data, and drafting the report, along with E.Y.., E.N.O. and A.H.W. All authors provided critical reviews and final approval of the manuscript."

"Funding Funding was provided for this project by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA."